News | 01 August 2026
Glenmark Pharma Q1 FY27 revenue rises 23% to Rs. 4,018.5 crore
The company's EBITDA rose 38.6% year-on-year to Rs. 804.8 crore, while EBITDA margin improved to 20.03%
The company's EBITDA rose 38.6% year-on-year to Rs. 804.8 crore, while EBITDA margin improved to 20.03%
The company's EBITDA grew 33.5% year-on-year to Rs. 93.1 crore, with the EBITDA margin expanding to 22.0%, an improvement of 190 basis points over the corresponding quarter last year
The company's EBITDA stood at Rs. 4,417.7 crore, up 2.7% from the corresponding quarter last year, with an EBITDA margin of 28.9%
Standalone revenue reaches Rs. 206.96 crore, while profit before tax climbs nearly 18% year-on-year
Consolidated revenue from operations rises 13%, while profit before tax jumps 42% on strong operational performance
Consolidated income from operations rises to Rs. 46.63 crore, while profit more than triples sequentially on improved operational performance
Company evaluating legal options after pricing regulator seeks recovery related to Symbicort Turbuhaler for 2016–2025 period
EBITDA margin climbs to 36.6% and PAT rises 31.8% YoY, even as the company ramps up R&D spend and greenfield capacity across its API and CDMO businesses
Domestic and Africa businesses drive a strong quarter even as Middle East disruptions dent Asia sales; Equirus Securities retains REDUCE rating citing rising costs and stretched valuations
The company also reduced its net debt by Rs. 11.9 crore during the quarter, maintaining a Net Debt-to-EBITDA ratio of 1.52x despite increased working capital investments
Supported by focused therapy expansion, new product launches and improved field-force productivity, company also entered the Top 50 Indian pharmaceutical companies by market ranking
The acquisition of Aequitas Healthcare is expected to significantly strengthen Jagsonpal's specialty portfolio and provide immediate access to more than 1,000 hospitals across India
The move aimed at creating a focused API business under RPG Active Pharma comes with an initial investment of up to Rs. 243 crore
Ashland reported 6% growth in sales volumes year-over-year, with gains across its entire portfolio
Former Sai Life Sciences executive to lead chemical development and strengthen Syngene's R&D capabilities
Generic version of Merck's BRIDION targets a $1.6 billion US market, expands Glenmark's injectables portfolio
Leadership changes strengthen API business and global finance function
As the company's domestic branded formulations business grows 14%, GLP-1 brand Sundae emerges as market leader by prescriptions
Efficient conclusion to the Talc Litigation that eliminates expense associated with litigating remaining roughly 76,000 ovarian Talc claims
Regulated Markets business surges 42%, EBITDA rises 87% as company expands US portfolio and manufacturing capacity
Subscribe To Our Newsletter & Stay Updated
